Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 May 1;81(5):336-338.
doi: 10.1097/FJC.0000000000001411.

Proprotein Convertase Subtilisin Kexin-9 Inhibitors (PCSK9i) in Atherosclerotic Cardiovascular Disease: Real-World Data Welcome

Francesco Moroni  1 , Michael P Ayers  1 , Dave L Dixon  2 , Antonio Abbate  1
Affiliations
Comment

Proprotein Convertase Subtilisin Kexin-9 Inhibitors (PCSK9i) in Atherosclerotic Cardiovascular Disease: Real-World Data Welcome

Francesco Moroni et al. J Cardiovasc Pharmacol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Comment on

References

    1. Dixon DL, Trankle C, Buckley L, et al. A review of PCSK9 inhibition, its effects beyond LDL receptors. J Clin Lipidol. 2016;10:1073–1080.
    1. Sabatine MS. PCSK9 inhibitors: clinical evidence, implementation. Nat Rev Cardiol. 2019;16:155–165.
    1. Santos RD, Stein EA, Hovingh GK, et al. Long-term evolocumab in patients with familial hypercholesterolemia. J Am Coll Cardiol. 2020;75:565–574.
    1. Kastelein JJP, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36:2996–3003.
    1. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722.

MeSH terms